Ingelvac Provenza®: Articles

Additional Reading

Get an in-depth look at the impact of influenza A virus in swine (IAV-S) on growing pigs and current management strategies aimed to reduce IAV-S transmission.

Support Pig Performance With Broad Cross-Protection Against IAV-S

Ingelvac Provenza®, now indicated for vaccination against influenza H1N1, H1N2, and H3N2, provides a strong foundation for respiratory health.

Read more about broad cross-protection
Managing IAV-S: New Data Show Significant Improvement in Average Daily Gain (ADG) and Mortality

Studies have shown that vaccination with Ingelvac Provenza® can be a valuable tool in current IAV-S protocols with a positive vaccine impact measured by standard performance targets.

Read more about building a strong immune foundation throughout the herd
A Valuable Tool to Protect Against Influenza A Virus in Swine (IAV-S)

The use of key performance indicators, including average daily gain (ADG) and variation (the spread of weights across a group of pigs), is essential in helping assess the success of IAV-S protocols. This in-field evaluation supports Ingelvac Provenza® as a strong foundation for respiratory health.

Read more about the positive impact on key performance measures with Ingelvac Provenza®
Pathogen Burden: IAV-S and the Impact on Growing Pigs

Growing pigs in the U.S. face the threat of numerous respiratory pathogens throughout their growing period, creating a significant impact on productivity and profitability.

Read more about pathogen burden through all production phases
Paradigm Shift: IAV-S in Pigs: Shifting the Approach to Protection

Once considered a seasonal, "simple" virus, influenza A virus in swine (IAV-S) has become an endemic dilemma with detrimental effect on performance and profitability. Ongoing IAV-S infection is not confined to the nursery; it impacts all phases of a swine operation, making it clear that traditional management strategies are no longer as effective or dependable as they once were.

Read more about individual protection for individual pigs
Industry Voice: A New Generation of Protection Against Influenza A Virus in Swine (IAV-S)

Posing a serious threat to performance, influenza A virus in swine (IAV-S) can have a widespread impact on productivity and profitability. IAV-S is one of the top three diseases affecting pigs in all phases of production,^1,2 and can lead to economic losses of more than $10 per head when present with concurrent infections.³ It can also lead to subsequent respiratory infections that can impact pig performance, including mortality and culls.

Read more about the first live attenuated influenza vaccine for pigs

References: 1. Vincent AL, Ma W, Lager KM, et al. Efficacy of intranasal administration of a truncated NS1 modified-live influenza virus vaccine in swine. Vaccine. 2007;25(47):7999–8009. 2. USDA APHIS, VS, NAHMS. Swine 2012 Part II: Reference of swine health and health management in the United States, 2012. February 2016. 3. Dykhuis Haden C, Painter T, Fangman T, Holtkamp D. Assessing production parameters and economic impact of swine influenza, PRRS and Mycoplasma hyopneumoniae on finishing pigs in a large production system. In: Proceedings of the 43rd American Association of Swine Veterinarians Annual Meeting; March 10–13, 2012; Denver, CO: 75–76.